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Objectives The purpose of this study was to assess the determinants of ventricular tachycardia (VT) recurrence in patients
who underwent VT ablation for post-infarction VT.
Background The factors that predict recurrence of VT after catheter ablation in patients with prior infarctions are not well
described.
Methods Catheter ablation was performed in 98 consecutive patients (88 males [90%]; mean age 67  10 years; ejec-
tion fraction 27  13%) with post-infarction VT. Electrograms from the implantable cardioverter-defibrillator
were analyzed, and VTs were classified as clinical, nonclinical, or new clinical.
Results A total of 725 VTs were induced during the ablation procedure. All VTs were targeted. In 76 patients, 105 clini-
cal VTs were inducible. Critical sites were identified with entrainment mapping and pace-mapping (10 of 12
matching leads) for 75 of 105 clinical VTs (71%) and for 278 of 620 nonclinical VTs (45%). Post-ablation, the
clinical VT was not inducible in any patient, and all VTs were rendered noninducible in 63% of the patients. Over
a mean follow-up period of 35  23 months, 65 of 98 patients (66%) had no recurrent VTs and 33 (34%) had
VT recurrence. A new VT occurred in 26 of 33 patients (79%), and a prior clinical VT recurred in 7 patients (21%).
Patients with recurrent VT had a larger scar area as assessed by electroanatomic mapping compared with pa-
tients without recurrent VTs (93  40 cm2 vs. 69  30 cm2; p  0.002). In patients with repeat procedures, the
majority of inducible VTs for which a critical area could be identified were at a distance of 6  3 mm to the prior
ablation lesions.
Conclusions Patients with recurrent VTs have a larger scar as assessed by electroanatomic mapping. Most recurrent VTs were
new, and the majority of these VTs were mapped to the vicinity of prior ablation lesions in patients with repeat
procedures. (J Am Coll Cardiol 2013;61:66–73) © 2013 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.07.059Although ablation for post-infarction ventricular tachycar-
dia (VT) is effective in reducing frequent implantable
cardioverter-defibrillator (ICD) discharges, recurrent VTs
still occur in many patients depending on the duration of
follow-up. The reasons for recurrence are unclear because
most of these arrhythmias are only documented by an ICD.
ICD electrograms have been shown to have distinct mor-
phological characteristics enabling different VT morpholo-
gies to be distinguished (1). The purpose of the current
study was to assess the reasons for VT recurrence based on
comparisons of ICD electrograms recorded during and after
the ablation procedure.
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Patient characteristics. Ninety-eight patients (88 [90%]
male; mean age 67  10 years; ejection fraction 27  13%)
with post-infarction VT and an implanted ICD were
referred for catheter ablation of VT between January 2004
and April 2011 (Table 1). All patients had a history of
myocardial infarction (anterior in 32 [33%], inferior in 66
[67%]). Before ablation, all patients had failed to respond to
antiarrhythmic drug treatment. Sixty-one patients (62%)
See page 74
were being treated with amiodarone, and 15 (25%) of the 61
were treated with a combination of amiodarone and mexi-
letine. Fourteen patients (14%) were treated with sotalol, 3
(3%) with mexiletine, 3 (3%) with dofetilide, and 1 (1%)
with verapamil at the time of ablation.
The indications for VT ablation were ICD discharges in
84 patients (86%), recurrent palpitations in 26 (27%), and
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January 8, 2013:66–73 Ventricular Tachycardia Recurrenceincessant VT in 13 (13%). Ten patients (10%) had under-
gone an unsuccessful ablation procedure before referral.
Before the ablation procedure, a stress test and/or cardiac
catheterization was performed. Nineteen patients had a
nuclear stress test, 67 patients had a cardiac catheterization,
and 5 patients had both a nuclear stress test and cardiac
catheterization. Two patients underwent an exercise stress
test. In 5 patients with VT storm and renal insufficiency,
neither a stress test nor a catheterization was performed. In
11 patients, a revascularization procedure was performed
before the procedure.
Electrophysiology study, mapping, and ablation. The
study protocol was approved by the institutional review
board at the University of Michigan. After written informed
consent was obtained, a multipolar electrode catheter was
inserted into a femoral vein and was positioned in the right
ventricular apex. A 7-F multipolar catheter was placed at the
His bundle position. Programmed ventricular stimulation
was performed from 2 right ventricular sites using up to 4
extrastimuli (2). The protocol was continued until either
refractoriness or a coupling interval of 200 ms was reached
with a minimum of 3 extrastimuli or if 5 shocks were
delivered to terminate VT. For all induced VTs, ICD
recordings were performed with near- and far-field record-
ings, and these were compared with the previously docu-
mented VTs from the ICD. If none of the clinical VTs was
induced, programmed stimulation was repeated with iso-
proterenol at 2 g/min if there was no inducible ischemia
present before the ablation procedure.
An electroanatomic mapping system (CARTO, Biosense
Webster, Inc., Diamond Bar, California) was used in all
patients, with an 8-F mapping/ablation catheter that had a
3.5-mm irrigated tip electrode and a 2-mm ring electrode
separated by 1 mm (Thermocool, Biosense Webster, Inc.).
In 7 of 98 patients, a 4-mm tip catheter was used; in 2
patients, an 8-mm tip catheter was used; and in 3 patients,
both a 4-mm and an 8-mm tip catheter were used. In the
remaining 86 patients, a 3.5-mm irrigated-tip catheter was
used. Intracardiac electrograms were filtered at 50 to 500
Hz. The intracardiac electrograms and leads V1, I, II, and
II were displayed on an oscilloscope and recorded at a
peed of 100 mm/s. Systemic heparinization with an acti-
ated clotting time 250 s was maintained throughout the
rocedure.
Patient Characteristics (N  98)Table 1 Patient Characteristics (N  98)
Age (yrs) 67 10
Male 88 (90)
Left ventricular ejection fraction (%) 27 13
Location of myocardial infarction
Anterior 32 (33)
Inferior 66 (67)
Patients taking amiodarone 61 (62)qValues are mean  SD or n (%).Left ventricular access was ob-
ained by using a retrograde aor-
ic approach and a trans-septal
pproach in 3 patients. A left
entricular endocardial voltage map
ith a mean of 429  184 points
as constructed during sinus
hythm in 81 patients and during
paced rhythm in 17 patients. Pace-mapping was per-
ormed at low voltage, which was defined as a bipolar
oltage 1.5 mV. A total of 347  169 low-voltage sites
ere sampled per patient. Capture of at least 2 consecutive
eats to allow for adequate analysis for pace-mapping was
chieved at 56  23 sites per patient. Pace-mapping was not
erformed if the catheter was close to a site (3 mm) where
ace-mapping was previously performed.
Bipolar pace-mapping was performed at 10 mA and a pulse
idth of 2 ms. If no capture occurred, the pacing output was
ncreased to 20 mA. Post-ablation stimulation was repeated at
he same pulse strength, and ablation was repeated if capture
as still present.
Radiofrequency energy was delivered at a power of 35 to
0 W targeting an impedance drop of 10 ohms using a
.5-mm open-irrigated tip catheter (Thermocool, Biosense
ebster). For an 8-mm tip catheter (n  5), a power of 70
was used, with a target temperature of 60 C°. For 4-mm
onirrigated tip catheters (n  7), a power of 50 W with a
emperature of 60°C was used.
All inducible VTs were targeted for ablation. Radiofre-
uency ablation was performed at critical sites of the VT
e-entry circuit. A critical site was defined as a site showing
oncealed entrainment with matching stimulus-QRS and
lectrogram-QRS intervals (3) or where VT terminated
uring pacing without global capture (4). Entrainment
apping was performed within the low-voltage area. Sites
ith pre-systolic or discrete systolic activity were sought
5–7). Entrainment mapping was performed at these sites,
nd radiofrequency energy was delivered if concealed en-
rainment was demonstrated or if there was VT termination
y a subthreshold pacing stimulus. If delivery of radiofre-
uency energy failed to terminate VT within 30 to 60 s, the
atheter was moved to an alternative site.
If a VT was not hemodynamically tolerated, a site was
onsidered critical if there was a matching pace-map. A
RS-morphology match was required in at least 10 of 12
eads. Once a site with a matching pace-map was identified,
he site was labeled and radiofrequency energy was delivered.
fter assessing for capture post-ablation, the catheter was
oved to a different site where pace-mapping was again
erformed. If a hemodynamically tolerated VTwas reproducibly
nducible, this VT was targeted with entrainment mapping ini-
ially. This was followed by pace-mapping throughout the scar.
Radiofrequency energy was delivered for 60 to 120 s
nd/or until the capture threshold post-ablation was10 to
0 mA. When there were matching pace-maps, radiofre-
Abbreviations
and Acronyms
ICD  implantable
cardioverter-defibrillator
VT  ventricular
tachycardiauency ablation was performed in the entire area in which
F
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Ventricular Tachycardia Recurrence January 8, 2013:66–73the match was present. If there was a prior inferior wall
myocardial infarction, a linear ablation lesion was created to
connect the infarct scar with the mitral annulus. Otherwise,
no linear lesions were created.
If no clinical VTs were inducible, radiofrequency energy
was delivered at sites with isolated potentials and fraction-
ated electrograms. The ablation endpoint was noncapture
with pacing stimuli, similar to ablation sites identified by
pace-mapping.
After ablation, the entire stimulation protocol was re-
peated at 2 right ventricular sites. If VTs remained induc-
ible, further mapping and ablation were performed until a
critical site was no longer identifiable.
Classification of VTs. The ICD electrograms of VTs that
were documented before the VT ablation procedure were
classified as clinical VTs. Induced VTs were correlated with
the real-time morphology of the ICD electrograms to assess
whether a VT was clinical (Fig. 1). This was done by visual
comparison as previously described (1). Induced VTs that
were not previously documented by the ICD were defined as
previously undocumented nonclinical VTs. VTs that were
documented during follow-up were compared with both
clinical VTs and the VTs induced during the ablation
procedure. If a new VT morphology was detected during
follow-up, this was defined as a new clinical VT.
Two observers independently compared the ICD electro-
grams before, during, and after ablation. Discrepancies were
Figure 1 Near and Far-Field ICD Electrograms
(A) Implantable cardioverter-defibrillator (ICD) recordings of a clinical ventricular
tachycardia (VT). Near-field recordings are on top, far-field recordings are on
bottom. (B) Real-time ICD recordings of the induced clinical VT during the elec-
trophysiology procedure. On top are near-field recordings; the bottom panel
shows far-field electrograms. The electrograms match the recorded electro-
grams by the ICD (A). (C) Real-time recordings of a VT that was induced during
the ablation procedure but was not previously recorded by the ICD before the
ablation. This VT was classified as nonclinical.mresolved by consensus. The kappa value was 0.88 for
agreement that a particular real-time tracing from the ICD
programmer during the VT induction matched or did not
match with a spontaneous VT. Both observers were blinded
in the post hoc analysis.
In 68 of 98 patients, both near- and far-field ICD
electrograms were available for analysis during the initial
ablation procedure. In 30 patients only, either a near-field
electrogram or a far-field electrogram was available for the
clinical VT. In 21 of these 30 patients, comparison of the
electrograms revealed that a single induced VT matched
with the stored ICD electrogram of a clinical VT. In 3
patients, the ICD-stored electrograms of the clinical VTs
were similar to 2 of the induced VTs. In 6 patients, the
ICD-stored electrograms of the clinical VTs did not match
any of the real-time ICD recordings of the induced VT.
Therefore, in 27 of 30 patients (90%), all induced VTs could
be classified as clinical or nonclinical.
Data analysis. In patients with recurrent VTs and repeat
procedures, the location of critical sites of inducible VTs
were analyzed with respect to the prior ablation procedure.
Specifically, we assessed whether:
1. Critical sites of new VTs were located adjacent to a
prior area of ablation. In addition to the topographic
correlation of the electroanatomic maps (Fig. 2), to
precisely correlate both procedures, we determined
whether these noncapturing sites were new and due to
ablation at the initial procedure or existed before the
initial ablation procedure. Pace-mapping or entrain-
ment mapping was performed to identify critical sites
(Fig. 3) and to correlate with the location of prior ablation
lesions (Figs. 2 and 3). The distance of new sites with
noncapture to sites critical for new VTs was deter-
mined. The critical sites were defined as being adja-
cent to prior ablation lesions if they were not separated
by points where capture with a different morphology
occurred. In patients without new areas of noncapture,
prior ablation points from previous procedures were
identified by aligning both electroanatomic maps us-
ing similar fiducial points (aortic cusp, mitral annulus,
and left ventricular apex). The coordinates of the
ablation points of the initial procedure were labeled and
displayed in a customized MATLAB program. After
aligning the fiducial points of both maps, the distance
between prior ablation points and sites with matching
pace-maps were determined.
2. Critical sites of induced VTs were located in scar areas
that were not thought to participate in ventricular
arrhythmias based on the initial mapping procedure.
The closest distance of ablation sites from the previous
procedure and new critical sites was measured as
outlined here.
ollow-up. Before discharge, 2 patients required repeat
blation procedures. All patients were seen every 3 to 6
onths in an ICD device clinic. If a patient previously was
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January 8, 2013:66–73 Ventricular Tachycardia Recurrencereceiving amiodarone, this medication was continued at the
same dose. Amiodarone was discontinued if there were
adverse effects (9 of 61 patients [15%]). The dose was
reduced from 400 to 200 mg/day if patients had no adverse
effects and no arrhythmias 3 to 6 months after the proce-
dure. Amiodarone eventually was discontinued in 14 pa-
tients in whom no VT was inducible at the end of the
procedure. Twelve patients (12%) were treated with sotalol,
7 (7%) with mexiletine, 2 (2%) with dofetilide, and 2 (2%)
with verapamil.
Statistical analysis. Continuous variables are expressed as
mean  SD and were compared by using the Student t test.
Discrete variables were compared by using the Fisher exact
test or by chi-square analysis, as appropriate. A p value
0.05 was considered significant.
Results
Recordings of VTs before ablation. A total of 331 VTs
were documented by using ICD electrograms before the
ablation procedure (3  4 VTs per patient). In 37 of 98
atients (38%), there was only 1 documented VT based on
CD electrogram analysis. Multiple VTs were documented
n the remaining patients. The clinical VTs had a mean
ycle length of 356  74 ms; when induced in the
lectrophysiology laboratory, their mean cycle length was
66  100 ms (p  0.11). However, 145 induced nonclini-
al VTs had VT cycle lengths (30 ms) similar to those of
he clinical VTs. A mean of 2  2 VTs per patient with
imilar VT cycle lengths (30 ms) compared with the
Figure 2 Sequential Electroanatomic Maps
Left panel: Electroanatomic map of the initial ablation procedure in a patient with
the locations of radiofrequency ablation lesions (brown tags). Middle panel: Elect
sites where no capture was achieved with pacing. During the initial procedure, no
with capture showing a distinct VT morphology that was induced during the repeat
capturing areas (hatched) indicating the potential course of a re-entry circuit (arrolinical VT were induced. 2nducible VTs during the ablation procedure. A total of
25 VTs were induced by programmed stimulation, and 147
Ts (20%) were reproducibly inducible (Table 2). A total of
05 of 725 induced VTs (14%) were clinically documented
efore ablation, and 86% of the induced VTs were previ-
usly not documented (6  5 VTs per patient). In 76
atients (78%), at least 1 clinical VT was induced (1 1 per
atient). In 11 patients, programmed stimulation was re-
eated during isoproterenol infusion, and a clinical VT was
nduced in 7 additional patients. In the remaining patients,
emonstration of incomplete revascularization precluded
he use of isoproterenol. In 22 patients (22%), a clinical VT
as not inducible. There were no significant differences in
linical characteristics between patients with and without
nducible clinical VT. In these patients, sites with isolated
otentials were also targeted. There was no difference in
utcome whether this approach was performed compared
ith the approach in which clinical VTs were targeted with
ace-mapping (recurrences occurred in 9 of 22 vs. 24 of 76
atients; p  0.41).
apping and ablation. Critical endocardial sites were
dentified for 75 of 105 clinical VTs (71%) and for 278 of
20 nonclinical VTs (45%), and radiofrequency energy was
pplied at these locations. In 16 of 105 clinical VTs (15%)
nd 26 of 620 nonclinical VTs (4%), critical sites were
dentified by entrainment mapping. Nonglobal capture oc-
urred in 4 clinical and 1 nonclinical VT. Pace-mapping was
sed to identify critical sites of 55 of 105 clinical VTs and
ent ventricular tachycardia (VT) 3 months after the initial VT ablation. Shown are
omic map obtained during the repeat ablation procedure. Gray tags indicate
ithout capture were identified in this area. Sites with blue tags indicate sites
on procedure but not during the initial procedure. Right panel: Schema of non-
ed on the pace-mapping data (shown in Fig. 3). MVA  major valve annulus.recurr
roanat
sites w
ablati
w) bas51 of 620 nonclinical VTs.
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Ventricular Tachycardia Recurrence January 8, 2013:66–73After ablation, programmed stimulation was repeated in
95 of 98 patients (97%). In 60 of 95 patients (63%), no VT
was inducible post-ablation. The clinical VTs that were
induced before ablation were no longer inducible in all
patients in whom programmed ventricular stimulation was
repeated at the end of the procedure. Fifty-four of 725 VTs
(7%) were inducible, and 671 VTs (93%) were no longer
inducible. No critical endocardial sites could be identified
for the 54 inducible VTs. In the patients in whom VT was
inducible post-ablation, VT was inducible with triple extra-
stimuli in 24 patients, double extrastimuli in 9, and a single
extrastimulus in 2. The manner of VT induction did not
correlate with recurrence of VT (7 of 24 [29%] vs. 4 of 9
[44%] vs. 1 of 2 [50%], respectively; p  0.63). The cycle
ength of the inducible VT did not correlate with VT
ecurrence (358  96 ms vs. 332  57 ms; p  0.25).
Furthermore, there was no significant difference in scar area
between patients with and without inducible VT at the end
Figure 3 Origin of VT Occurring After Ablation Procedure
Electroanatomic map and pace maps illustrating mapping data of a ventricular tac
anatomic map of the repeat procedure illustrated in Figure 2. Below on the left is
QRS) intervals from sites 1, 2, and 3 (arrows), which are surrounded by nonexcita
tags) during the repeat ablation procedure.of the procedure (83  33 cm2 vs. 73  37 cm2; p  0.23). rFor 307 of 725 VTs (42%), no critical endocardial sites
ere identified, yet these VTs were no longer inducible
ost-ablation.
ollow-up after the initial procedure. The mean
ollow-up period after the procedure was 35 23 months (1
o 89 months) (Table 3). No patients were lost to follow-up.
ixty-five of 98 patients (66%) did not have VT recurrence.
n 16 of 33 patients, a new VT resulted in VT recurrence;
n 7 patients, only a prior clinical VT recurred. In 10 of 33
atients, both a prior clinical VT and a new VT occurred.
atients with recurrent VTs had a larger endocardial scar
rea as assessed by electroanatomic mapping. Whether a VT
as inducible at the end of the ablation procedure did not
redict recurrence.
In the 33 patients with recurrent VTs, ICD electrograms
howed 89 different VTs recurring after ablation (Table 4).
ifteen of 89 VT events (17%) were due to VTs that were
reviously recorded by the ICD (prior clinical VT). The
ia (VT) circuit of the patient shown in Figure 2. Top left insert shows the electro-
f the mapped VTs with matching pace-maps and different stimulus-QRS (Stim-
eas. Top right insert indicates where ablation lesions were delivered (brownhycard
one o
ble aremaining 74 VTs were not previously documented. With
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January 8, 2013:66–73 Ventricular Tachycardia Recurrencerespect to the prevalence of the recurrent VTs, a median of
77% were due to new VTs, and the remaining 23% were due
to the previously documented VTs.
Repeat mapping procedures. In 14 patients (14%), a
repeat procedure was performed (Figs. 2 to 4). Two of the
14 patients had recurrence of only a prior clinical VT, and
6 of the patients had recurrence of a new VT. In 6 of 14
patients, both a prior clinical and a new VT recurred. A total
of 49 different VTs were documented before the repeated
ablation procedure (4  3 VTs per patient; 8 of these VTs
were previously documented, and 41 were new VTs).
During the repeat procedures, 78 VTs (6  3 VTs per
patient) were induced. These included 8 previously docu-
mented clinical VTs in 8 patients. New clinical VTs that
were not documented before or during the initial ablation
procedure were inducible at the repeat procedure in all 14
patients. Critical sites were identified for 47 of 78 inducible
VTs (60%). The majority of the critical sites that were
identified were for new VTs (85%) that were not docu-
mented before or during the initial ablation procedure. The
majority of the critical sites were adjacent to previous
ablation lesions (53%), and the second largest group (32%)
was localized to areas that were previously not thought to
participate in the arrhythmias (based on pace-mapping data
in the initial procedure). The mean distance between sites
Induced and No Induced Clinical VTsDuring the Ablation ProcedureTable 2 Induced and No Induced Clinical VTsDuring the Ablation Procedure
Variable
Induced Clinical VT
(n  76)
No Induced Clinical VT
(n  22) p Value
Age (yrs) 67 9 67 10 0.88
Male 67 (88) 21 (95) 0.45
Left ventricular ejection
fraction (%)
28 13 25 14 0.38
Anterior infarction (%) 23 (30) 9 (41) 0.45
Patients taking
amiodarone
51 (67) 10 (45) 0.07
Clinical VTs
No. of clinical VTs 3 4 3 2 0.52
Cycle length, ms 359 74 343 77 0.15
Induced VTs
All 7 4 9 6 0.22
Clinical VTs 1 1 NA
Nonclinical VTs 6 4 9 6 0.013
Identified critical sites
All 3 2 4 3 0.13
Clinical VTs 1 1 NA
Nonclinical VTs 2 2 4 3 0.002
Radiofrequency ablation
parameter (min)
Procedure time 416 118 418 122 0.92
Fluoroscopy time 69 25 67 27 0.73
Radiofrequency
ablation duration
64 45 73 48 0.47
Induced VTs after the
ablation
26/73 (36) 9/22 (41) 0.65
Values are mean  SD or n (%).
VT ventricular tachycardia.critical for new VTs and noncapturing sites arising in areasof prior ablation was 6  3 mm, and it was 11  7 mm for
new VTs arising from areas without prior ablation (p 
0.0004). Critical sites for prior clinical VTs accounted for the
remaining 15% of critical areas that were identified in these
patients. These VTs were previously either not inducible or
were targeted by pace-mapping or entrainment mapping.
After the procedure, no VT could be induced in 11 patients.
After the last procedure, 75 of 98 patients had no additional VT
recurrences, resulting in a total success rate of 77%.
In 1 patient with recurrent VTs, an epicardial procedure
was performed, and the recurrent clinical VT was success-
fully ablated. This was the only patient in this series in
whom an epicardial procedure was performed.
Complications. Periprocedural complications consisted of
pericardial tamponade that responded to percutaneous
drainage (n  1), stroke secondary to thromboembolism
(n  1), heart failure (n  1), groin hematoma requiring
blood transfusion and surgery (n  1), and hematuria
Recurrent and No-Recurrent VTsAfter the Ablati n ProcedureTable 3 Recurr nt and No-Recurrent VTsAfter the Ablation Procedure
Variable
Recurrent VT
(n  33)
No Recurrent
VT (n  65) p Value
Age (yrs) 66 10 68 9 0.39
Male 31 (94) 57 (88) 0.49
Left ventricular ejection fraction (%) 25 12 29 14 0.26
Anterior infarction (%) 14 (42) 18 (28) 0.14
Patients taking amiodarone after
the initial procedure
15 (45) 35 (54) 0.43
Scar area (cm2) 93 40 69 30 0.002
Recurrent VTs
Clinical VTs only 7 NA
Clinical VTs and new VTs 8 NA
New VTs only 18 NA
Clinical VTs
No. of clinical VTs 4 5 3 3 0.29
Cycle length (ms) 350 77 359 73 0.34
No induced clinical VTs 9 (27) 13 (20) 0.41
Reproducible induced clinical VTs 13 (39) 30 (46) 0.52
Induced VTs
All 8 5 7 5 0.48
Clinical VTs 1 1 1 1 0.74
Nonclinical VTs 7 5 6 5 0.44
Not identified critical sites of
clinical VTs
14 (42) 24 (37) 0.60
Identified critical sites
All 4 3 3 2 0.49
Clinical VTs 1 1 1 1 0.21
Nonclinical VTs, n 3 3 3 2 0.30
Radiofrequency ablation parameter
(min)
Procedure time 437 126 405 114 0.23
Fluoroscopy time 73 26 67 25 0.26
Radiofrequency ablation duration 73 48 63 44 0.35
Induced VTs after the ablation
Nonclinical VTs 11/32 (34) 24/63 (38) 0.72
Clinical VTs 0/32 (0) 0/63 (0) 1.0Values are mean  SD or n (%).
VT  ventricular tachycardia.
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Ventricular Tachycardia Recurrence January 8, 2013:66–73(n  1). Two patients had recurrent VT storm and
required another ablation procedure before discharge.
Follow-up. The total follow-up period after the first pro-
cedure was 39  23 months (3 to 89 months); after the last
rocedure, the follow-up was 34  18 months (7 to 56
onths). Twelve patients died during follow-up. One
atient died secondary to worsening heart failure, 1 patient
ied suddenly with recurring ventricular arrhythmias, and
0 patients died of noncardiac causes.
There was no significant difference in mortality between
atients with and without recurrence of VTs (6 of 33
18%] vs. 6 of 65 [9%]; p  0.20). Amiodarone was
iscontinued in 23 patients. There was no difference in
T recurrence regardless of whether amiodarone was
iscontinued (p  0.77).
iscussion
T recurred in approximately one third of the patients in
his series. The main reason for VT recurrence was the
Recurrent VTs After the Ablation ProcedureTable 4 Recurrent VTs After the Ablation Procedure
Variable
Patients With
New VTs
(n  26)
Patients With
Only Prior
Clinical VTs
(n  7) p Value
Age (yrs) 66 10 65 11 0.80
Male 24 (92) 7 (100) 1.00
Left ventricular ejection fraction (%) 23 11 34 14 0.03
Anterior infarction (%) 10 (38) 4 (57) 0.42
Patients on amiodarone after the
initial procedure
15 (58) 3 (43) 0.67
Scar area (cm2) 95 29 84 67 0.50
Clinical VTs
No. of clinical VTs 4 5 2 1 0.21
Cycle length (ms) 374 74 440 52 0.001
Induced clinical VTs 19 (73) 5 (71) 1.00
Induced VTs
All 9 5 4 4 0.04
Clinical VTs 1 1 1 0 0.29
Nonclinical VTs 8 5 4 4 0.06
Noninduced clinical VTs 3 5 1 1 0.26
Not identified critical sites of
clinical VTs
11 (42) 3 (43) 1.00
Identified critical sites
All 4 3 3 3 0.36
Clinical VTs 1 1 1 1 0.75
Nonclinical VTs, n 3 3 2 3 0.44
Radiofrequency ablation parameter
(min)
Procedure time 437 118 434 161 0.96
Fluoroscopy time 76 29 72 25 0.69
Radiofrequency ablation duration 76 47 63 55 0.55
Induced VTs after the ablation
Nonclinical VTs 9/25 (36) 2/7 (29) 1.00
Clinical VTs 0/25 (0) 0/7 (0) 1.00
Values are mean  SD or n (%).
VT  ventricular tachycardia.ccurrence of new VTs that were most often mapped toites adjacent to scar from prior ablation lesions or areas that
ere initially not thought to contain VT circuits. Patients
ith VT recurrence had more extensive scar than patients
ithout recurrent VT.
T recurrence. VT recurrence after ablation has been
escribed in up to 57% of patients (8) with prior myocardial
nfarctions. Previous efforts to analyze the reasons for VT
ecurrence have been mainly limited by the inability to
dequately characterize the recurring VT. These attempts
ere confined to comparisons of VT cycle lengths, which
re subject to inaccuracy due to cycle length variation
econdary to antiarrhythmic treatment or due to different
Ts with similar cycle lengths in a given patient. The
orphology of ICD electrograms has been used successfully
o identify clinical VTs (1) and is well suited to analyze
easons for recurrent VTs.
The main reason for VT recurrence in this study was the
ccurrence of new VTs. The majority of VTs that recurred
ere different from the initially induced and targeted VTs.
hese circuits are either new circuits or modifications of
re-existing circuits. A clear distinction between these 2
ossibilities is impossible because all of the circuits were not
apped. It is intriguing, however, that critical areas were
ound adjacent to clusters of ablation lesions deployed
uring the initial ablation procedure that resulted in the lack
f local capture during the repeat procedure. Nonexcitable
ost-infarction scar has been described to form part of a
xed border of the re-entry circuit (9). It is therefore
ossible that some of the ablation lesions from prior
rocedures formed the borders for some of the recurring
ew VTs. Complete linear lesions are difficult to achieve in
he ventricle, yet complete linear lesions may be one way to
educe VT recurrence post-ablation. Real-time intraproce-
ural magnetic resonance imaging may help to assure that
blation lesions are complete.
Figure 4 Mapped VTs During Repeat Procedures
Patients who underwent repeat ventricular tachycardia (VT) ablations
illustrating the location of the critical sites for VT circuits. CE  concealed
entrainment; PM  pace-mapping; RF  radiofrequency ablation.
ms
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January 8, 2013:66–73 Ventricular Tachycardia RecurrenceIn patients with repeat procedures, about one-third of the
mapped VTs were located in areas that were not thought to
be involved in the arrhythmogenic substrate during the
initial procedure and were therefore not targeted for abla-
tion. Lack of inducibility most likely accounted for the
inability to identify these areas participating in the arrhyth-
mogenic substrate. It is therefore not surprising that in
patients with VT recurrence, the infarct scars as measured
by using electroanatomic mapping were larger.
Clinical VTs that were thought to be effectively ablated
during the initial procedure sometimes recurred. In 2
patients with repeat procedures, the VTs recurred despite
the VT terminating during radiofrequency ablation at a site
with concealed entrainment. It is important to note that
despite the inability to induce a particular VT at the end of
a procedure, these VTs can still recur.
Study limitations. Left-sided programmed stimulation
was not performed in all patients in whom the clinical VT
could not be induced. In addition, programmed stimulation
with isoproterenol was not performed in all patients due to
incomplete revascularization. This might have reduced the
rate of noninducible patients and may have resulted in a
lower recurrence rate.
Because only a near- or a far-field ICD electrogram of the
clinical VT was available in one-third of patients for the
initial procedure, a few clinical VTs might not have been
correctly identified. However, all patients had their ICDs
reprogrammed to record both near- and far-field electro-
grams after the initial procedure.
The procedure was guided by entrainment mapping and
pace-mapping. Interestingly, a critical area was identified by
using these mapping techniques in only about 50% of the
inducible VTs. This finding suggests that many VT circuits
had epicardial or intramural components or were composed
of functional elements. Other potential reasons for the lower
yield of pacing sites matching the induced VTs include the
possibility that sites with matching pace-maps within the
scar were simply missed and that the delivery of radiofre-
quency energy at sites of matching pace-maps altered the
scar substrate. A complex 3-dimensional arrhythmogenic
substrate with shared circuits (10) might explain why an
epicardial procedure was necessary in only 1 of the 98
patients.Although pace-mapping only was performed at low-
voltage sites, there were many more low-voltage sites than
pace-mapping sites. This discrepancy was due to catheter
instability and dislodgement before pacing, inconsistent
capture, and exclusion of sites 3 mm from prior pace-
apping sites.
Although there was no difference in mortality in this
mall study, it was not powered to detect a difference in
ortality between patients with and without recurrence.
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